Everest to Start China Phase III Trial of ADC For Urothelial Cancer

Everest Medicines was approved to start a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer. The candidate is a first-in-class, antibody-drug conjugate (ADC) aimed at TROP-2, a membrane antigen that is over-expressed in many epithelial cancers. In 2019, Everest entered an $835 million agreement ($65 million upfront) to acquire China rights to the ADC from Immunmedics, now part of Gilead .  Everest completed a $451 million IPO in Hong Kong three months ago. More details.... Stock Symbols: (HK: 1952) (NSDQ: GILD) Share this with colleagues: // //